Aduro Biotech, Inc.

Brief Description

Aduro is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations. The company’s lead technology platforms are based on LADD (live, attenuated, double-deleted Listeria mononcytogenes) and CDNs (cyclic dinucleotides). Both are proprietary platforms. LADD strains have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. 


  • 2008. Aduro Biotech founded.
  • 2011. Aduro Biotech licenses technology developed at UC Berkeley, including attenuated Listeria monocytogenes mutants and methods to engineer these bacteria to stimulate the immune system as vaccines for immunotherapy. 
  • 2016. An investment of $7.5 million by Aduro Biotech created a UC Berkeley Immunotherapeutics and Vaccine Research Initiative (IVRI), which brings infectious disease, cancer, and immunology experts from academia and industry together to propel basic and early applied research toward weaponizing the body's immune system against disease.
  • 2018. Launch of the Aduro Biotech-UC Berkeley Underrepresented Postdoctoral Fellowship Program in the UC Berkeley College of Chemistry supports researchers from diverse backgrounds, and builds a pipeline of scientific talent for Aduro Biotech R&D laboratories.
  • 2020. Aduro Biotech merges with Chinook Therapeutics. The combined company operates as Chinook Therapeutics.


Dan Portnoy, David Raulet, Russell Vance

Tech Category

  • Medical Therapeutics

In the News

Join the IPIRA Mailing List




Accessibility | Nondiscrimination | Privacy